Furthermore, those on insulin in the WG medication group are likely to have had T2D for a longer duration, indicating a more advanced stage of diabetes that could exacerbate corneal nerve damage directly or through comorbidities such as obesity, abnormal lipid profiles, and renal impairment. This evidence concerns the gene INS and type 2 diabetes mellitus.